• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket

    6/20/23 8:10:28 AM ET
    $ACLX
    $BFRI
    $BMR
    $CANO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACLX alert in real time by email

    Gainers

    • Evelo Biosciences, Inc. (NASDAQ:EVLO) shares gained 91.5% to $0.2298 in pre-market trading. Evelo Biosciences shares jumped around 45% on Friday after the company won U.S. Patent for prebiotic compositions and methods of use thereof for modulation of the microbiome.
    • EBET, Inc. (NASDAQ:EBET) shares surged 57% to $0.3010 in pre-market trading. EBET said Aspire shut down activities in Germany on May 7.
    • Biofrontera Inc. (NASDAQ:BFRI) shares rose 47.7% to $0.65 in pre-market trading. Biofrontera recently started a contract manufacturer development of a portable photodynamic therapy lamp for use with Ameluz-PDT.
    • Tivic Health Systems, Inc. (NASDAQ:TIVC) shares rose 29.2% to $0.1273 in pre-market trading after gaining 7% on Friday. Tivic Health recently reported worse-than-expected first-quarter sales results.
    • voxeljet AG (NASDAQ:VJET) gained 14.8% to $2.33 in pre-market trading after gaining around 5% on Friday.
    • SunCar Technology Group Inc. (NASDAQ:SDA) shares climbed 13.9% to $25.00 in pre-market trading after gaining around 4% on Friday.
    • Oncorus, Inc. (NASDAQ:ONCR) shares gained 13.6% to $0.1497 in pre-market trading after climbing around 70% on Friday.
    • Cano Health, Inc. (NYSE:CANO) rose 13.6% to $1.42 in pre-market trading as the company announced a change in its executive leadership intended to advance execution of the Company's strategy for stockholder value creation.
    • Ideanomics, Inc. (NASDAQ:IDEX) gained 10.2% to $0.0907 in pre-market trading. The company’s board determined to discontinue operations of its Unit Justly Markets LLC.
    • Revelation Biosciences, Inc. (NASDAQ:REVB) rose 10.6% to $1.14 in pre-market trading after declining 7% on Friday.

    Losers

    • Surgalign Holdings, Inc. (NASDAQ:SRGA) fell 45.9% to $0.66 in pre-market after gaining over 3% on Friday.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) fell 37% to $0.2834 in pre-market trading. Faraday Future Intelligent Electric said it would defer the second delivery phase of its limited edition FF 91 2.0 Futurist Alliance. The company has pinned the delay on the supplier’s timing constraints and the time needed for additional safety testing.
    • Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) fell 24% to $2.12 in pre-market trading. Dragonfly Energy Holdings will be awarded a new U.S. patent addressing the streamlined production of conventional Li-ion ion batteries and nonflammable solid-state lithium batteries in the U.S.
    • Arcellx, Inc. (NASDAQ:ACLX) fell 22.3% to $27.80 in pre-market trading after the company reported clinical hold for its iMMagine-1 Phase 2 clinical program.
    • Beamr Imaging Ltd. (NASDAQ:BMR) shares dropped 14.4% to $2.49 in pre-market trading.
    • Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) fell 14.2% to $0.6524 in pre-market trading after adding 13% on Friday.
    • Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) fell 12.8% to $0.2074 in pre-market trading after jumping over 32% on Friday.
    • IronNet, Inc. (NASDAQ:IRNT) shares dropped 11.8% to $0.1852 in pre-market trading. IronNet shares jumped 46% on Friday after a JV affiliated with C5 delivered a proposal to which it would provide funding for operation shortfalls, make changes to management composition and and take steps to remove the company from public securities markets
    • Missfresh Limited (NASDAQ:MF) shares fell 10.9% to $0.5345 in pre-market trading. Missfresh recently revealed receipt of Nasdaq notification regarding delisting.
    • WeWork Inc. (NYSE:WE) fell 10.5% to $0.22 in pre-market trading. WeWork stockholders approved amendment to charter to effect reverse stock split of Class A and Class C common stock at a ratio in range of 1-for-10 at Annual General Meeting.

     

    Now Read This: Market Volatility Decreases; S&P 500 Settles Lower

    Get the next $ACLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLX
    $BFRI
    $BMR
    $CANO

    CompanyDatePrice TargetRatingAnalyst
    Arcellx Inc.
    $ACLX
    2/12/2026$82.00Buy → Neutral
    Rothschild & Co Redburn
    Arcellx Inc.
    $ACLX
    1/7/2026$100.00Buy
    UBS
    Arcellx Inc.
    $ACLX
    12/22/2025$100.00Overweight
    Wells Fargo
    Arcellx Inc.
    $ACLX
    11/18/2025Peer Perform
    Wolfe Research
    Arcellx Inc.
    $ACLX
    10/16/2025$129.00Buy
    Stifel
    Arcellx Inc.
    $ACLX
    6/17/2025$110.00Buy
    Citigroup
    SunCar Technology Group Inc.
    $SDA
    6/10/2025$3.50Outperform
    Oppenheimer
    Dragonfly Energy Holdings Corp.
    $DFLI
    3/25/2025$9.00 → $1.50Buy → Neutral
    Alliance Global Partners
    More analyst ratings

    $ACLX
    $BFRI
    $BMR
    $CANO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arcellx downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Arcellx from Buy to Neutral and set a new price target of $82.00

    2/12/26 7:20:24 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Arcellx with a new price target

    UBS resumed coverage of Arcellx with a rating of Buy and set a new price target of $100.00

    1/7/26 9:34:38 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo initiated coverage on Arcellx with a new price target

    Wells Fargo initiated coverage of Arcellx with a rating of Overweight and set a new price target of $100.00

    12/22/25 8:37:37 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    $BFRI
    $BMR
    $CANO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global Chief Executive Officer Aydt Matthias bought $100 worth of Series A Preferred Stock (1 units at $100.00) (SEC Form 4)

    4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

    1/30/25 9:36:52 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    Global Chief Exec. Officer Aydt Matthias disposed of $100 worth of Series A Preferred Stock (1 units at $100.00) and bought $100 worth of Series A Preferred Stock (1 units at $100.00), decreasing direct ownership by 50% to 1 units (SEC Form 4)

    4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

    6/25/24 4:11:43 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    Hayward Andrea Maria bought $1,900 worth of shares (2,000 units at $0.95) (SEC Form 4)

    4 - IDEANOMICS, INC. (0000837852) (Issuer)

    2/8/24 4:52:14 PM ET
    $IDEX
    Auto Manufacturing
    Consumer Discretionary

    $ACLX
    $BFRI
    $BMR
    $CANO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream

    MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

    3/31/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $BFRI
    $BMR
    $CANO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Valauri Christina Rizopoulos

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    4/2/26 9:49:13 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Wolf Lisa G

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    3/19/26 9:14:41 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Gilson Michelle

    4 - Arcellx, Inc. (0001786205) (Issuer)

    3/19/26 6:26:45 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    $BFRI
    $BMR
    $CANO
    SEC Filings

    View All

    Amendment: SEC Form SC 14D9/A filed by Arcellx Inc.

    SC 14D9/A - Arcellx, Inc. (0001786205) (Subject)

    4/1/26 4:50:25 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC TO-T/A filed by Arcellx Inc.

    SC TO-T/A - Arcellx, Inc. (0001786205) (Subject)

    4/1/26 4:34:18 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Dragonfly Energy Holdings Corp.

    10-K - Dragonfly Energy Holdings Corp. (0001847986) (Filer)

    3/30/26 5:38:34 PM ET
    $DFLI
    Industrial Machinery/Components
    Miscellaneous

    $ACLX
    $BFRI
    $BMR
    $CANO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arcellx Inc.

    SC 13G - Arcellx, Inc. (0001786205) (Subject)

    11/22/24 4:12:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dragonfly Energy Holdings Corp.

    SC 13D/A - Dragonfly Energy Holdings Corp. (0001847986) (Subject)

    11/21/24 6:10:38 PM ET
    $DFLI
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $BFRI
    $BMR
    $CANO
    Leadership Updates

    Live Leadership Updates

    View All

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

    Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company's commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert. This strengthening of the Company's management follows the recent announcement of an agreement to acquire all rights and assets related to Ameluz® and RhodoLED® for the US market, including the FDA approval and al

    8/11/25 4:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

    5/23/25 4:05:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $BFRI
    $BMR
    $CANO
    Financials

    Live finance-specific insights

    View All

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dragonfly Energy to Report Preliminary Fourth Quarter and Full Year 2025 Financial and Operational Results on March 16, 2026

    RENO, Nev., March 13, 2026 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) ("Dragonfly Energy" or the "Company"), an industry leader in energy storage and battery technology, today announced that the Company will release its preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, March 16, 2026. The earnings press release will be followed by a conference call on March 16, 2026, at 4:30 PM Eastern Time. Interested investors and other parties may access the live webcast via the link found here or through the Events and Presentations page within the Investor Relations section of Dragonfly Energ

    3/13/26 7:30:00 AM ET
    $DFLI
    Industrial Machinery/Components
    Miscellaneous

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care